Prodrug of melphalan
- Trade Name: Pepaxto (Oncopeptides)
- Indications: Relapsed or refractory multiple myeloma (in combination with dexamethasone)
- Synonym: Melflufen
- Class: Alkylating agent
- Half-life: 70 minutes
- FDA Approval Date: 02/26/2021
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: Based on its mechanism of action, melphalan flufenamide can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
